Prieto Introduces World’s Fastest-Charging Battery That Charges in 3 Minutes
22.5.2023 16:03:00 EEST | Business Wire | Press release
Prieto Battery, Inc., a world leader in advanced lithium-ion battery technology, unveiled the most recent prototype of its patented 3D interdigitated battery that delivers groundbreaking performance:
- 3-minute hyper-fast charge
- Operates and charges in extremely low (-30 degrees C) and high (+100 degrees C) temperatures
- Nonflammable
All three attributes of Prieto’s lithium-ion battery were tested and validated by a third-party accredited battery testing lab.
Hyper-Fast Charge
“Prieto’s battery will charge faster than you can fill your car’s gas tank,” said Mike Rosenberg, Prieto CEO. “When you charge your car faster than gassing up, range is no longer a hindrance and everyone becomes a potential EV buyer.”
Due to its 3D architecture, Prieto’s battery fully charges in three minutes and achieves a 50% charge in 90 seconds, regardless of size.
“A three-minute charge fundamentally changes how companies can design their products and how consumers use them,” added Rosenberg.
All-Weather Extreme Temperature Operation
The Prieto 3D battery delivers the industry’s widest temperature operation. Not only does it operate at -30 degrees C (-22 degrees F), but it also charges at that temperature. The battery also operates and is safe at temperatures as high as +100 degrees C (212 degrees F).
“Prieto’s battery is the only battery that we are aware of that will not only operate, but will also charge at -30 degrees Celsius,” explained Rosenberg. “As we learned this past winter when extreme cold weather hit North America, many people were left stranded with dead EVs. Our battery would have allowed these EVs to continue to operate and charge, instilling confidence in drivers to rely on their EVs even in extreme temperatures.”
Nonflammable
Prieto’s 3D architecture and design ensure that the battery is not flammable or combustible. A third-party lab conducted the gold standard “nail penetration test” on Prieto’s battery that resulted in no fire or explosion, and the battery continued to operate.
“Prieto’s battery operates safely and will not catch fire like traditional lithium-ion batteries,” Rosenberg said. “The 3D architecture and the materials we use ensure that our batteries will not experience thermal runaways or fires, which gives consumers peace of mind.”
3D Interdigitated Technology
“Our founder, Dr. Amy Prieto, reimagined the entire architecture of a conventional battery and developed the first 3D interdigitated battery,” said Rosenberg. “We’re introducing a better architecture and a better process, which results in a better battery and a superior consumer experience. This is truly the next evolution that will redefine the way we power our lives.”
Prieto’s 3D architecture is completely different from all other batteries. Today’s batteries use a decades-old 2D architecture that must always compromise between energy storage and fast charging. In 2D batteries, energy can only flow in one direction across a two-dimensional plane. To charge, lithium ions must flow from one surface to the other, resulting in serious limitations. Thicker 2D batteries store more energy, but the long ion pathways result in slow charging. Thinner 2D batteries can charge faster but cannot store much energy.
“We’ve dramatically shortened the diffusion length in any direction, which takes charging to hyper-speed and delivers more power and energy storage than 2D batteries,” said Dr. Prieto, founder and chief technology officer of Prieto. “The core of our battery looks like a thin copper sponge, and the ions only have to travel from one strand to the next, a fraction of the distance in traditional 2D batteries.”
Prieto’s battery is designed to deliver five times the power density (20C discharge rate) and up to three times the energy density of conventional 2D batteries. It is customizable to any size or application, making it ideal for anything from electric vehicles to power tools, medical devices to mobile phones and small home appliances.
Simple, Cost-Effective Manufacturing
Prieto’s new battery boasts a unique manufacturing advantage because it is made from low-cost, sustainable materials with a simple and scalable process. Prieto uses a proven water-based electroplating process at room temperature and its process requires no dry rooms, clean rooms, or other expensive equipment.
“From day one I prioritized manufacturing ahead of the battery design, and I knew to reimagine the battery we would first have to simplify production to scale up quickly, efficiently, and affordably,” said Dr. Prieto.
Prieto’s current laboratory manufacturing yield rates are more than 90%.
“We now turn our focus to commercialization as we finalize plans to build our pilot manufacturing facility,” said Rosenberg. “Our high yield rates, combined with our simple and familiar manufacturing process used in many other industries, will ultimately result in much lower costs than traditional lithium-ion batteries and gives us a great degree of confidence.”
Prieto is currently in discussions for manufacturing and applications with potential partners.
About Prieto
Prieto developed a proprietary 3D interdigitated lithium-ion battery that delivers transformational performance, such as hyper-fast charging, wide temperature operations and is safe, at a competitive cost. Its battery is customizable to all shapes and sizes for use in electric vehicles, consumer electronics and commercial equipment. Prieto also patented a unique electroplating manufacturing process that uses non-toxic materials without the need for highly specialized facilities. The company was founded in 2009. Prieto’s lab and headquarters are in Fort Collins, Colorado. Visit prietobattery.com.
About Dr. Amy Prieto
Dr. Prieto is the founder and chief technology officer at Prieto. She earned her doctorate in Chemistry from the University of California, Berkeley, and completed her postdoctoral work at Harvard University. She received the Presidential Early Career Award for Scientists and Engineers for this battery technology and is recognized by the Smithsonian Institution, where her innovation is on display in its museum in Washington, D.C.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005396/en/
Contact information
Lisa Metzger
lisametzger@avocetcommunications.com
John Hall
john@avocetcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
